Difference between revisions of "Colorectal cancer - historical"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) |
|||
Line 47: | Line 47: | ||
!style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | !style="width: 20%"|[[Levels_of_Evidence#Comparative_efficacy|Comparative Efficacy]] | ||
|- | |- | ||
− | |[https:// | + | |[https://doi.org/10.3816/ccc.2004.n.004 Price et al. 2004] |
|1996-1998 | |1996-1998 | ||
|style="background-color:#1a9851"|Phase 3 (C) | |style="background-color:#1a9851"|Phase 3 (C) | ||
Line 60: | Line 60: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
− | # Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. [https:// | + | # Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. [https://doi.org/10.3816/ccc.2004.n.004 link to original article] [https://pubmed.ncbi.nlm.nih.gov/15025796/ PubMed] |
==Fluorouracil & Semustine {{#subobject:ddfd74|Regimen=1}}== | ==Fluorouracil & Semustine {{#subobject:ddfd74|Regimen=1}}== | ||
<div class="toccolours" style="background-color:#ee6b6e"> | <div class="toccolours" style="background-color:#ee6b6e"> |
Revision as of 13:58, 22 December 2023
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main colorectal cancer page for current regimens.
5 regimens on this page
5 variants on this page
|
Metastatic disease, first-line
Fluorouracil & Methotrexate (MF)
MF: Methotrexate & Fluorouracil
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Wils et al. 2003 | 1992-1994 | Phase 3 (C) | MF & PALA | Did not meet endpoints of RR/PFS/OS |
Chemotherapy
References
- Wils J, Blijham GH, Wagener T, De Greve J, Jansen RL, Kok TC, Nortier JW, Bleiberg H, Couvreur ML, Genicot B, Baron B; EORTC Gastrointestinal Group. High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. Eur J Cancer. 2003 Feb;39(3):346-52. link to original article PubMed
Fluorouracil & Mitomycin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Price et al. 2004 | 1996-1998 | Phase 3 (C) | Fluorouracil & Mitomycin; chronomodulated | Did not meet endpoints of FFS/OS |
Chemotherapy
References
- Price TJ, Ross PJ, Hickish T, Tait D, Norman AR, Ford HE, Middleton G, Sumpter K, Hill M, Oates J, Cunningham D. Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer. 2004 Feb;3(4):235-42. link to original article PubMed
Fluorouracil & Semustine
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Baker et al. 1976 | 1973-1974 | Phase 3 (C) | 5-FU | Superior ORR |
Engstrom et al. 1982 (ECOG E4275) | NR | Phase 3 (E-switch-ic) | 1. 5-FU, Semustine, Vincristine 2. 5-FU, Dacarbazine, Semustine 3. 5-FU, Dacarbazine, Semustine, Vincristine 4. 5-FU & Hydrea |
Did not meet endpoints of RR/OS |
Chemotherapy
- Fluorouracil (5-FU) 400 mg/m2 IV once per day on days 1, 8, 15, 22, 29, 36
- Semustine (MeCCNU) 175 mg/m2 PO once on day 1
42-day cycles
References
- Baker LH, Talley RW, Matter R, Lehane DE, Ruffner BW, Jones SE, Morrison FS, Stephens RL, Gehan EA, Vaitkevicius VK; Southwest Oncology Group. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs methyl-CCNU plus bolus weekly 5-FU: a Southwest Oncology Group study. Cancer. 1976 Jul;38(1):1-7. link to original article contains dosing details in abstract PubMed
- ECOG E4275: Engstrom PF, MacIntyre JM, Douglass HO Jr, Muggia F, Mittelman A. Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275). Cancer. 1982 Apr 15;49(8):1555-60. link to original article PubMed
FOLFOX chronotherapy
FOLFOX: FOLinic acid (Leucovorin), Fluorouracil, OXaliplatin
Regimen
Study | Dates of enrollment | Evidence | Comparator | Comparative Efficacy |
---|---|---|---|---|
Lévi et al. 1997 | 1991-1993 | Phase 3 (E-switch-ic) | FOLFOX; CI | Superior TTF |
Note: This schedule is "chronomodulated"; see paper for details.
Chemotherapy
- Leucovorin (Folinic acid) 300 mg/m2 IV over 12 hours once per day on days 1 to 5, given second, with 5-FU
- Fluorouracil (5-FU) 600 mg/m2 IV over 12 hours once per day on days 1 to 5, given second, with leucovorin
- Oxaliplatin (Eloxatin) 20 mg/m2 IV over 12 hours once per day on days 1 to 5, given first
21-day cycles
References
- Lévi F, Zidani R, Misset JL; International Organization for Cancer Chronotherapy. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet. 1997 Sep 6;350(9079):681-6. link to original article contains dosing details in manuscript PubMed